ARETHA: cARdiomems vEriciguaT Heart fAilure (A double-blind randomized placebo-controlled trial of vericiguat in heart failure patients with CardioMEMS™ HF System)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514111-10-00

Enrollment

Registered

2024-09-20

Start date

2024-12-06

Completion date

Unknown

Last updated

2025-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure with reduced ejection fraction (HFrEF)

Brief summary

To evaluate the diastolic pulmonary artery pressure (dPAP) lowering effect of vericiguat in comparison to placebo

Detailed description

To evaluate the NT-proBNP reducing effect of vericiguat compared with placebo

Interventions

DRUGVerquvo 2.5 mg film-coated tablets

DRUGVerquvo 10 mg film-coated tablets

DRUGPLACEBO

DRUGVerquvo 5 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To evaluate the diastolic pulmonary artery pressure (dPAP) lowering effect of vericiguat in comparison to placebo	—

Secondary

Measure	Time frame
To evaluate the NT-proBNP reducing effect of vericiguat compared with placebo	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026